BEDFORD  Mass--(BUSINESS WIRE)--Anika Therapeutics  Inc  (NASDAQ: ANIK)  a global  integrated orthopedics medicines company specializing in therapeutics based on its proprietary hyaluronic acid technology  today announced that the US Food & Drug Administration’s (FDA) Office of Combination Products has assigned CINGAL® to the Center for Drug Evaluation and Research (CDER) as the lead center for premarket review